Opdualag (nivolumab and relatlimab)

pCPA File Number: 22581

Negotiation Status:

Active Negotiation

Indication(s):

Opdualag (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma

Sponsor/Manufacturer:

Bristol Myers Squibb

CDA-AMC Project Number:

PC0329-000

pCPA Engagement Letter Issued:

2024-06-21

Negotiation Process Concluded:

Not Applicable